Literature DB >> 24271138

Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis.

Xiang-Hua Ye1, Zhi-Bin Bu, Jie Feng, Ling Peng, Xin-Biao Liao, Xin-Li Zhu, Xiao-Li Sun, Hao-Gang Yu, Dan-Fang Yan, Sen-Xiang Yan.   

Abstract

The previous published data on the association between TP53 codon 72, intron 6, and intron 3 16 bp polymorphisms and lung cancer risk remained controversial. This meta-analysis of literatures was performed to derive a more precise estimation of the relationship. 38 publications with 51 studies were selected for this meta-analysis, including 17,337 cases and 16,127 controls for TP53 codon 72 (from 43 studies), 2,201 cases and 2,399 controls for TP53 intron 6 (from four studies), and 4,322 cases and 4,558 controls for TP53 intron 3 16 bp (from four studies). When all the eligible studies were pooled into the meta-analysis of codon 72 polymorphism, there was significant association between lung cancer risk and codon 72 polymorphism in any genetic model (dominant model: OR = 1.13, 95 % CI 1.05-1.21; recessive model: OR = 1.14, 95 % CI 1.02-1.27; additive model: OR = 1.19, 95 % CI 1.05-1.33). In the subgroup analysis by ethnicity, histological type, source of control, and smoking status, significantly increased risks were observed in subgroups such as Asians, Caucasians, lung squamous cell carcinoma patients for Asians, population-based study, hospital-based study, non-smokers, and smokers. When all the eligible studies were pooled into the meta-analysis of intron 6 polymorphism, there was significant association between lung cancer risk and intron 6 polymorphism in dominant model (OR = 1.27, 95 % CI 1.11-1.44). When all the eligible studies were pooled into the meta-analysis of intron 3 16 bp polymorphism, there was significant association between lung cancer risk and intron 3 16 bp polymorphism in dominant model (OR = 1.12, 95 % CI 1.02-1.23) and additive model (OR = 1.41, 95 % CI 1.04-1.90). Additionally, when one study was deleted in the sensitive analysis, the results of TP53 intron 3 16 bp duplication polymorphism were changed in the dominant model (OR = 1.11, 95 % CI 0.87-1.42) and additive model (OR = 1.01, 95 % CI 0.65-1.56). In summary, this meta-analysis indicates that codon 72 and intron 6 polymorphisms show an increased lung cancer risk. A study with the larger sample size is needed to further evaluated gene-environment interaction on TP53 codon 72, intron 6, and intron 3 16 bp polymorphisms and lung cancer risk.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24271138     DOI: 10.1007/s11033-013-2871-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  72 in total

1.  A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints.

Authors:  Roger M Harbord; Matthias Egger; Jonathan A C Sterne
Journal:  Stat Med       Date:  2006-10-30       Impact factor: 2.373

2.  Association study of TP53 polymorphisms with lung cancer in a Korean population.

Authors:  Hae-Yun Jung; Young Mi Whang; Jae Sook Sung; Hyoung Doo Shin; Byung Lae Park; Jun Suk Kim; Sang Won Shin; Hee Yun Seo; Jae Hong Seo; Yeul Hong Kim
Journal:  J Hum Genet       Date:  2008-03-25       Impact factor: 3.172

3.  Glutathione-S-Transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility.

Authors:  J To-Figueras; M Gene; J Gomez-Catalan; C Galan; J Firvida; M Fuentes; M Rodamilans; E Huguet; J Estape; J Corbella
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1996-05       Impact factor: 4.254

4.  Detection of oncogenic viruses SV40, BKV, JCV, HCMV, HPV and p53 codon 72 polymorphism in lung carcinoma.

Authors:  Laura Giuliani; Terese Jaxmar; Caterina Casadio; Marisa Gariglio; Assunta Manna; Domenico D'Antonio; Kari Syrjanen; Cartesio Favalli; Marco Ciotti
Journal:  Lung Cancer       Date:  2007-04-02       Impact factor: 5.705

5.  P53 polymorphisms and haplotypes in lung cancer.

Authors:  R Birgander; A Själander; A Rannug; A K Alexandrie; M I Sundberg; J Seidegård; G Tornling; G Beckman; L Beckman
Journal:  Carcinogenesis       Date:  1995-09       Impact factor: 4.944

6.  TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis.

Authors:  Lili Yan; Deqiang Zhang; Chengwen Chen; Yumin Mao; Yi Xie; Yao Li; Yan Huang; Baohui Han
Journal:  Int J Cancer       Date:  2009-12-15       Impact factor: 7.396

7.  Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung.

Authors:  S Sato; Y Nakamura; E Tsuchiya
Journal:  Cancer Res       Date:  1994-11-01       Impact factor: 12.701

8.  Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer.

Authors:  K Kawajiri; K Nakachi; K Imai; J Watanabe; S Hayashi
Journal:  Carcinogenesis       Date:  1993-06       Impact factor: 4.944

9.  Allelic frequency of a p53 polymorphism in human lung cancer.

Authors:  A Weston; L S Perrin; K Forrester; R N Hoover; B F Trump; C C Harris; N E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1992 Sep-Oct       Impact factor: 4.254

Review 10.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

View more
  14 in total

1.  Interferon gamma +874 T/A polymorphism increases the risk of cervical cancer: evidence from a meta-analysis.

Authors:  Yifan Sun; Yu Lu; Qiliu Pen; Taijie Li; Li Xie; Yan Deng; Aiping Qin
Journal:  Tumour Biol       Date:  2015-02-04

Review 2.  The TP53 codon 72 Pro/Pro genotype may be associated with an increased lung cancer risk in North China: an updated meta-analysis.

Authors:  Xin Wang; Li-Ran Hao; Kai Yue
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 3.  Screening for lung cancer using low-dose computed tomography: concerns about the application in low-risk individuals.

Authors:  Jiu-Wei Cui; Wei Li; Fu-Jun Han; Yu-Di Liu
Journal:  Transl Lung Cancer Res       Date:  2015-06

4.  A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma.

Authors:  Yanding Zhao; Frederick S Varn; Guoshuai Cai; Feifei Xiao; Christopher I Amos; Chao Cheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

5.  Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population.

Authors:  Md Shaki Mostaid; Maizbha Uddin Ahmed; Mohammad Safiqul Islam; Muhammad Shahdaat Bin Sayeed; Abul Hasnat
Journal:  Tumour Biol       Date:  2014-07-18

6.  The rs7003908 (T>G) polymorphism in the XRCC7 gene and the risk of cancers.

Authors:  Min Xiao; Yongchun Shen; Lei Chen; Zenglin Liao; Fuqiang Wen
Journal:  Mol Biol Rep       Date:  2014-02-18       Impact factor: 2.316

7.  The Association between HMGA1 rs146052672 Variant and Type 2 Diabetes: A Transethnic Meta-Analysis.

Authors:  Aida Bianco; Eusebio Chiefari; Carmelo G A Nobile; Daniela Foti; Maria Pavia; Antonio Brunetti
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

8.  Interferon Gamma +874T/A Polymorphism Increases the Risk of Hepatitis Virus-Related Diseases: Evidence from a Meta-Analysis.

Authors:  Yifan Sun; Yu Lu; Taijie Li; Li Xie; Yan Deng; Shan Li; Xue Qin
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

9.  AXIN2 rs2240308 polymorphism contributes to increased cancer risk: evidence based on a meta-analysis.

Authors:  Zhitong Wu; Yifan Sun; Shifu Tang; Chunming Liu; Shengbo Zhu; Lili Wei; Hong Xu
Journal:  Cancer Cell Int       Date:  2015-07-04       Impact factor: 5.722

10.  Vitamin D Receptor Gene FOKI Polymorphism Contributes to Increasing the Risk of HIV-Negative Tuberculosis: Evidence from a Meta-Analysis.

Authors:  Chun Xu; Peijun Tang; Cheng Ding; Chang Li; Jun Chen; Zhenlei Xu; Yi Mao; Meiying Wu; Jun Zhao
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.